The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer
Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response
(DOI : 10.3390/cells11182866)
Information trouvée : Doctorante; membre de l'UMRS1113, Interface Recherche Fondamentale et Appliquée en
Cancérologie - IRFAC, Strasbourg, 2023